Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

SPONSORED – Neuropathy affects nearly 25 million Americans ... Health From Within Chiropractic has a better solution that does not involve drugs or surgery. Hear more about their 4-pronged ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...

We have gathered all the information for you in one convenient spot, but please keep in mind that these are subject to change. We do our best to keep everything updated, but something might be out of ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

2 University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School ... The patient was diagnosed with bilateral optic neuropathy; chronic use of linezolid was suspected as the ...

The company is preparing to submit an Investigational New Drug (IND) application by the end of 2024, with plans to begin Phase I clinical trials in the first quarter of 2025. To maximize the ...